SHINKEI Therapeutics

11:15 AM - 11:30 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
• SHINKEI is a CNS (Central Nervous System) disorders focused pharmaceutical company using the 505b2 regulatory strategy to redevelop existing pharmaceutical products for faster and better patient outcome. The pharmaceutical industry has over last few years largely neglected investing in the development of drugs for many CNS disorders. With reduced R&D spending and a need to boost productivity in finding new products, pharma increasingly relies on new concepts from partners like SHINKEI who are on the front lines of identifying unmet clinical needs.

• SHINKEI was co-founded by Suresh Borsadia and GP Singh, industry veterans, having the mix of commercial and scientific backgrounds. They are supported by a small but efficient team of professionals, advisors and consultants. The co-founders began their idea generation and development in 2017 with rigorous literature search, KOL discussions and enlisting the right R&D partners
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
MR-301
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CHAIRMAN
SHINKEI Therapeutics